1-叔丁基-1H-吡咯-2-甲醛 | 23373-78-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-叔丁基-1H-吡咯-2-甲醛
• 英文名称: 1-(1,1-dimethylethyl)-2-pyrrolecarboxaldehyde
• 英文别名: 1-tert-butyl-1H-pyrrole-2-carbaldehyde；1-tert-butyl-pyrrole-2-carbaldehyde；mono-t-butyl-pyrrole-2-carboxaldehyde；1-tert-Butyl-2-formyl-pyrrol；1-t-Butyl-2-formylpyrrol；1-tert-butylpyrrole-2-carbaldehyde
• CAS: 23373-78-6
• 化学式: C₉H₁₃NO
• mdl: MFCD07186505
• 分子量: 151.208
• InChiKey: VFGRWHIUIWPYOR-UHFFFAOYSA-N

物化性质

• 沸点：
  229.9±13.0 °C(Predicted)
• 密度：
  0.94±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-叔丁基-1H-吡咯-2-甲醛 在 四丁基氟化铵 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 1-(1,1-dimethylethyl)-2-<(3-pyridinyl)methyl>-4-formylpyrrole
  参考文献：
  名称：

  [(1H-Imidazol-1-yl)methyl]- and [(3-pyridinyl)methyl]pyrroles as thromboxane synthetase inhibitors

  摘要：

  Several [(1H-imidazol-1-yl)methyl]- and [(3-pyridinyl)methyl] pyrroles were prepared and evaluated in vitro as thromboxane synthetase inhibitors in human platelet aggregation studies. A number of structures, e.g. 10b,f,g,i (respective IC50 values: 1 microM, 50 nM, 42 nM, 44 nM) showed superior in vitro inhibition of TXA2 synthetase when compared to the standard dazoxiben (1). However, it was found that in vitro potency did not translate into nor correlate with in vivo activity when these compounds were evaluated in mice in a collagen-epinephrine-induced pulmonary thromboembolism model. (E)-1-Methyl-2-[(1H-imidazol-1-yl)methyl]-5-(2-carboxyprop-1-enyl) pyrrole (10b) was found to offer protection against collagen-epinephrine-induced mortality in mice, thereby demonstrating that oral administration is an effective route for absorption of this drug. Additional evidence for the oral effectiveness of 10b in lowering serum TXB2 levels was obtained by performing ex vivo radioimmunoassay experiments with rats. A 13-week study of 10b in rats with reduced renal mass was conducted in order to evaluate the role of TXA2 production in hypertension and renal dysfunction. Although serum and urinary TXB2 levels in rats were found to be lowered during this study by 10b, the levels of urinary protein excretion remained comparable to that of the control group.

  DOI：

  10.1021/jm00124a027
• 作为产物：
  描述：

  2-吡咯甲醛 、 氯代叔丁烷 在 AlCl₃ 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 1-叔丁基-1H-吡咯-2-甲醛
  参考文献：
  名称：

  Synthesis of 4-substituted pyrrole-2-carbaldehyde compounds

  摘要：

  本发明涉及一种制备4-取代吡咯-2-甲醛化合物的方法，包括反应：a.一种吡咯-2-甲醛化合物；和b.一种烷基化试剂；c.在至少一种催化剂的存在下，形成4-烷基取代的吡咯-2-甲醛化合物。

  公开号：

  US06441194B1

文献信息

• Direct and Efficient Synthesis of Pyrrole-3-carbaldehydes by Vilsmeier-Haack Formylation of Pyrroles with Sterically Crowded Amides
  作者：Mikhail Kuznetsov、Petr Ilyin、Alena Pankova

  DOI：10.1055/s-0031-1290763

  日期：2012.5

  Abstract A simple and convenient synthetic method to prepare N-substituted pyrrole-3-carbaldehydes by Vilsmeier–Haack formylation of pyrroles using sterically crowded formamides was developed. The dependence of the formylation regioselectivity on steric features of substrates and reagents is discussed. A simple and convenient synthetic method to prepare N-substituted pyrrole-3-carbaldehydes by Vilsmeier–Haack

  摘要 开发了一种简单方便的合成方法，该方法通过使用空间拥挤的甲酰胺，通过Vilsmeier-Haack对吡咯进行甲酰化来制备N-取代的吡咯3-甲醛。讨论了甲酰化区域选择性对底物和试剂空间特征的依赖性。 开发了一种简单方便的合成方法，该方法通过使用空间拥挤的甲酰胺，通过Vilsmeier-Haack对吡咯进行甲酰化来制备N-取代的吡咯3-甲醛。讨论了甲酰化区域选择性对底物和试剂空间特征的依赖性。
• Jasmonate derivatives and compositions thereof
  申请人：Nanocare Technologies, Inc.

  公开号：US10314918B2

  公开（公告）日：2019-06-11

  The disclosure describes jasmonate conjugates and nanocarried and/or microcarried jasmonate conjugates and pharmaceutical compositions thereof, as well as use thereof for treating or preventing angiogenesis-related or NF-κB-related disorders. Also disclosed are methods of making the conjugates.

  本公开描述了茉莉酸盐共轭物、纳米载体和/或微载体茉莉酸盐共轭物及其药物组合物，以及其在治疗或预防血管生成相关疾病或 NF-κB 相关疾病方面的用途。还公开了制造这些共轭物的方法。
• JASMONATE DERIVATIVES AND COMPOSITIONS THEREOF
  申请人：Nanocare Technologies, Inc.

  公开号：US20170368186A1

  公开（公告）日：2017-12-28

  The disclosure describes jasmonate conjugates and nanocarried and/or microcarried jasmonate conjugates and pharmaceutical compositions thereof, as well as use thereof for treating or preventing angiogenesis-related or NF-κB-related disorders. Also disclosed are methods of making the conjugates.
• US6433162B1
  申请人：——

  公开号：US6433162B1

  公开（公告）日：2002-08-13
• US6441194B1
  申请人：——

  公开号：US6441194B1

  公开（公告）日：2002-08-27